Seres Therapeutics, Inc. (MCRB)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
5.62 USD
-0.49
(-8.020%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.61 -0.01 (-0.010%) ⇩ (July 13, 2026, 5:06 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:32 a.m. EDT
The investment case here is severely compromised by a deteriorating business model and a broken capital structure. Fundamentally, the company is hemorrhaging cash with operating margins of nearly -58%, negative free cash flow exceeding $40 million annually, and a massive debt load relative to its tiny equity base. The balance sheet is fragile, with a debt-to-equity ratio of over 300, suggesting that any further operational shortfall could trigger distress. While the stock trades at a low absolute price, the valuation metrics are nonsensical given the losses, and the historical trajectory shows a catastrophic -98% decline over the last nine years, with the last two years seeing double-digit percentage drops. This is not a value opportunity; it is a value trap where the market has correctly priced out the risk of insolvency or failed clinical trials. On the short end, the technicals are weak, trading below key moving averages, and the options market is screaming caution with heavy put positioning and negligible call interest. There is no catalyst visible to reverse this multi-year decline, making this a security to avoid entirely. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.078194 |
| AutoETS | 0.080320 |
| AutoTheta | 0.082551 |
| AutoARIMA | 0.082648 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.016 |
| Excess Kurtosis | 0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 303.781 |
| Revenue per Share | 0.126 |
| Market Cap | 54,423,708 |
| Forward P/E | -0.85 |
| Beta | 0.10 |
| Website | https://www.serestherapeutics.com |
As of July 11, 2026, 4:32 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at strikes well above the current price (e.g., 10.0 and 12.5 for Jan 2027). Call activity is sparse and concentrated at lower strikes, while implied volatility remains extremely low across all expirations, indicating a lack of speculative optimism and a market pricing in continued stagnation or decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5885522 |
| Address1 | 101 Cambridgepark Drive |
| All Time High | 1,040.0 |
| All Time Low | 5.31 |
| Ask | 6.83 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 149,280 |
| Average Daily Volume3 Month | 79,808 |
| Average Volume | 79,808 |
| Average Volume10Days | 149,280 |
| Beta | 0.095 |
| Bid | 4.4 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.763 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.62 |
| Current Ratio | 1.646 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.0001 |
| Day Low | 5.32 |
| Debt To Equity | 303.781 |
| Display Name | Seres Therapeutics |
| Earnings Call Timestamp End | 1,762,349,400 |
| Earnings Call Timestamp Start | 1,762,349,400 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -83,804,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.254 |
| Enterprise To Revenue | 91.62 |
| Enterprise Value | 105,088,712 |
| Eps Current Year | -7.515 |
| Eps Forward | -6.575 |
| Eps Trailing Twelve Months | -5.2 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2327 |
| Fifty Day Average Change | -1.6127 |
| Fifty Day Average Change Percent | -0.22297344 |
| Fifty Two Week Change Percent | -58.855217 |
| Fifty Two Week High | 29.98 |
| Fifty Two Week High Change | -24.36 |
| Fifty Two Week High Change Percent | -0.8125417 |
| Fifty Two Week Low | 5.31 |
| Fifty Two Week Low Change | 0.30999994 |
| Fifty Two Week Low Change Percent | 0.058380403 |
| Fifty Two Week Range | 5.31 - 29.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,435,325,400,000 |
| Float Shares | 8,473,830 |
| Forward Eps | -6.575 |
| Forward P E | -0.85475284 |
| Free Cashflow | -41,538,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 66 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -52,304,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.117819995 |
| Held Percent Institutions | 0.24373 |
| Implied Shares Outstanding | 9,683,934 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,280,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Seres Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 54,423,708 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_222388947 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -46,899,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 59,168,836 |
| Number Of Analyst Opinions | 2 |
| Open | 5.94 |
| Operating Cashflow | -42,153,000 |
| Operating Margins | -58.399437 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 945 9626 |
| Post Market Change | -0.009999752 |
| Post Market Change Percent | -0.17793153 |
| Post Market Price | 5.61 |
| Post Market Time | 1,783,976,805 |
| Previous Close | 6.11 |
| Price Eps Current Year | -0.74783766 |
| Price Hint | 2 |
| Price To Book | 2.034021 |
| Price To Sales Trailing12 Months | 47.448742 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.554 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.49 |
| Regular Market Change Percent | -8.01964 |
| Regular Market Day High | 6.0001 |
| Regular Market Day Low | 5.32 |
| Regular Market Day Range | 5.32 - 6.0001 |
| Regular Market Open | 5.94 |
| Regular Market Previous Close | 6.11 |
| Regular Market Price | 5.62 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 333,522 |
| Return On Assets | -0.38876 |
| Return On Equity | -1.21873 |
| Revenue Per Share | 0.126 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 9,683,934 |
| Shares Percent Shares Out | 0.0162 |
| Shares Short | 157,327 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 478,817 |
| Short Name | Seres Therapeutics, Inc. |
| Short Percent Of Float | 0.021300001 |
| Short Ratio | 1.41 |
| Source Interval | 15 |
| State | MA |
| Symbol | MCRB |
| Target High Price | 22.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 17.0 |
| Total Cash | 29,834,000 |
| Total Cash Per Share | 3.081 |
| Total Debt | 80,499,000 |
| Total Revenue | 1,147,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.3337 |
| Two Hundred Day Average Change | -6.7137003 |
| Two Hundred Day Average Change Percent | -0.54433787 |
| Type Disp | Equity |
| Volume | 333,522 |
| Website | https://www.serestherapeutics.com |
| Zip | 2,140 |